Ratings New Horizon Health Limited

Equities

Market Closed - Hong Kong S.E. Other stock markets 04:08:30 2024-03-27 am EDT			5-day change	1st Jan Change
14.14 ^HKD	-19.75%		-.--%	-38.92%

Apr. 08	New Horizon Health Limited Announces Board Appointments	CI
Mar. 28	New Horizon Health Limited Announces Delay in Publication Annual Results for the Year Ended December 31, 2023	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's profit outlook over the next few years is a strong asset.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

With an expected P/E ratio at 99.04 and 18.42 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
NEW HORIZON HEALTH LIMITED	-38.92%	810M		-
BIOMÉRIEUX	-1.04%	12.47B		B+
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-17.29%	6.99B		B-
DIASORIN S.P.A.	-2.21%	5.1B		B
LANTHEUS HOLDINGS, INC.	+2.92%	4.27B		C
AUTOBIO DIAGNOSTICS CO., LTD.	-4.79%	4.27B		C
10X GENOMICS, INC.	-50.07%	3.45B		D+
ANDON HEALTH CO., LTD.	+7.65%	2.61B	-	-
VITROLIFE AB	-15.92%	2.08B		B-
MYRIAD GENETICS, INC.	-3.34%	1.67B		C

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality